Oral Pathology
Nooshin Mohtasham; Narges Ghazi; Kazem Anvari; Farnaz Mohajertehran; Tahmineh Organji; Mehdi Shahabinejad
Abstract
Background & Objective: The present study investigated the relationship between invasive front (IF) of tumors and clinicopathological parameters including stage, grade, nodal involvement, lymphocytic host response (LHR), recurrence, overall survival (OS), and disease-free survival (DFS).Methods: ...
Read More
Background & Objective: The present study investigated the relationship between invasive front (IF) of tumors and clinicopathological parameters including stage, grade, nodal involvement, lymphocytic host response (LHR), recurrence, overall survival (OS), and disease-free survival (DFS).Methods: A total of 87 oral squamous cell carcinoma (OSCC) biopsies were evaluated. Clinical stage, grading, nodal involvement, time of recurrence, OS, and DFS were assessed. The number of tumor budding cells in the IF was measured by two pathologists with an optic microscope. IF was graded to low risk (<5) and high risk (>5), according to the counting of tumor budding as a single cancer cell or cluster cells. Also, LHR was reported in the IF as mild, moderate, and severe.Results: IF was reported in 43.7% of patients as a low-risk group and 49.4% as a high-risk group. LHR was also mild in 31%, moderate in 25.3%, and severe in 43.7% of the patients. Most of the patients were in stage IV (31%) and grade 1 (60.9%). The high risk IF group had a significant statistical relationship with stage (P=0.001), grade (P=0.039), five years OS (P=0.03), five years DSF (P=0.01), and lymph node involvement (P=0.007). The relation between LHR and stage of disease was significant (P=0.034).Conclusion: Considering the important role of histopathological reports in the treatment plan of patients and the relationship between IF and clinical parameters, IF evaluation in routine histopathological examinations, especially in the early stages of OSCC, seems to be necessary.
Neuropathology
Seyed Abbas Tabatabaei Yazdi; Masoomeh Safaei; Mehran Gholamin; Alireza Abdollahi; Fatemeh Nili; Mehdi Jabbari Nooghabi; Kazem Anvari; Majid Mojarrad
Abstract
Background & Objectives: Glioblastoma is the most common primary malignancy of the brain, the prognosis of which is poor. Immunotherapy with cancer/testis (CT) antigens is a novel therapeutic approach for glioblastoma. This study aimed to investigate the expression rate of MAGE-E1, GAGE, and SOX-6 ...
Read More
Background & Objectives: Glioblastoma is the most common primary malignancy of the brain, the prognosis of which is poor. Immunotherapy with cancer/testis (CT) antigens is a novel therapeutic approach for glioblastoma. This study aimed to investigate the expression rate of MAGE-E1, GAGE, and SOX-6 in glioblastoma tumors using the immunohistochemistry (IHC) method. Materials & Methods: Expression of MAGE-E1, GAGE, and SOX-6 were determined by IHC in 50 paraffin blocks of glioblastoma. The results were compared between variables including age, gender, tumor location, and Karnofsky performance status (Kps) score. Survival analysis was also performed. Results: The expression levels of SOX-6, MAGE-E1, and GAGE were 82%, 78%, and 76%, respectively. The relationship between CT antigens and age, gender, and tumor location was not significant, while the association between MAGE-E1 expression and age was statistically significant (p =0.002). High expression levels of SOX-6 and MAGE-E1 were associated with low Kps scores (p =0.034 and p <0.001, respectively). Survival analysis showed that age >40 and Kps score p =0.005 and p =0.018, respectively). Expression of MAGE-E1 and GAGE was negatively associated with overall 2-year survival (p =0.001 and p =0.021, respectively). Conclusion: The expression of all the three CT antigens, especially MAGE-E1 and SOX-6, was high in patients with glioblastoma. It can be concluded that these markers are ideal targets for immunotherapy in these patients. MAGE-E1 and SOX-6 can be considered as important markers in determining the prognosis of glioblastoma.
Kazem Anvari; Abdolazim Sedighi Pashaki; Mahmoud Reza Kalantari; Mehdi Seilanian Toosi; Mohammad Reza Ghavam Nasiri; Hamid Reza Raziee
Volume 4, Issue 1 , January 2009, , Pages 32-37
Abstract
Background and Objective: Approximately half of patients with diffuse large B-cell lymphoma are cured with current chemotherapy regimens. The purpose of this study was to evaluate Bax and Bcl2 expression and their relationship with the response to chemotherapy. Materials and Methods This study ...
Read More
Background and Objective: Approximately half of patients with diffuse large B-cell lymphoma are cured with current chemotherapy regimens. The purpose of this study was to evaluate Bax and Bcl2 expression and their relationship with the response to chemotherapy. Materials and Methods This study was a prospective analysis on 44 patients with diffuse large B-cell lymphoma. Their specimens were stained with immunohistochemistery method for Bax and Bcl2. The relationship between Bax/Bcl2 expression and the response to chemotherapy as well as some other prognostic factors were assessed. Results: Out of 44 patients, 29 were Bax+ and 15 Bax-, 31 Bcl2+ and 13 Bcl2-. We found a statistically significant relationship between IPI score and the response to chemotherapy (P = 0.002). The response rates were relatively better (but not significant) in cases with Bax + compared to Bax – and in patients with Bcl2- compared to Bcl2 + tumors. The combination of immunohistochemistery results for Bcl2 and Bax could predict relatively higher response rates in a way that those with Bax+ Bcl2- had a higher response compared to Bax- Bcl2+ ( 57%% VS.22%, p=0.15). Conclusion: Although we found a relatively higher responses in our cases with Bax + vs. Bax - and in those with Bcl2- vs. Bcl2 +, the differences were not statistically significant. We suggest further studies to confirm whether the Bcl2 and Bax expressions have any effect on the response to chemotherapy and whether they could be considered as predictor factors for chemotherapy response.
Mehdi Seilanian Toosi; Mohammad Reza Ghavam Nasiri; Kamran Ghafarzadegan; Azar Fani Pakdel; Roham Salek; Kazem Anvari
Volume 3, Issue 1 , January 2008, , Pages 5-10
Abstract
Background and Objective: P53 is a suppressive gene that plays a key role in DNA repair and apoptosis. The purpose of this study was to investigate the effect of P53 protein over-expression and some clinicopathological factors on the esophageal squamous cell carcinoma (SCC) response to neoadjuvant chemoradiotherapy. ...
Read More
Background and Objective: P53 is a suppressive gene that plays a key role in DNA repair and apoptosis. The purpose of this study was to investigate the effect of P53 protein over-expression and some clinicopathological factors on the esophageal squamous cell carcinoma (SCC) response to neoadjuvant chemoradiotherapy. Patients and Methods: In this retrospective cohort study, 44 patients with localized esophageal SCC undergoing neoadjuvant chemoradiotherapy (cisplatin + 5FU and 40 Gy in 20 fractions of irradiation) and surgery were evaluated. Pretreatment specimens were immunohistochemically assessed for p53 over-expression and scored according to the frequency of stained cells. The pathologic response in resected specimens was categorized as follows: complete response (CR), no evidence of malignant cell; partial response (PR), small foci of malignant cells and negative lymph nodes and minor response, macroscopic residual tumor or positive lymph nodes. Results: It was found out that p53 protein over-expression exists in 29 cases (65.9%). Following chemoradiotherapy, CR and PR were found in 9 (20.5%) and 19 cases (43.2%) respectively. There were also no significant association between tumor response and clinicopathological features such as sex (p = 1), age (p = 0.82), dysphagia grade (p = 0.82) and longitudinal length of the tumor (p = 0.59). No significant correlation was found between p53 expression and pathological response to preoperative chemoradiotherapy (p = 0.94). Conclusion: These findings suggest that p53 protein expression is not reliable for predicting the response to neoadjuvant chemoradiotherapy. There were also no correlations between pathological response to chemoradiotherapy and clinical features such as age, sex, dysphagia grade and longitudinal diameter of the tumor.
